Loading...
Avidity Biosciences, Inc.
RNA•NASDAQ
Healthcare
Biotechnology
$36.27
$3.06(9.21%)
Avidity Biosciences, Inc. (RNA) Financial Performance & Income Statement Overview
Review Avidity Biosciences, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
13.99%
↑ 13.99%
Operating Income Growth
-60.84%
↓ 60.84%
Net Income Growth
-51.87%
↓ 51.87%
Operating Cash Flow Growth
-152.70%
↓ 152.70%
Operating Margin
-4853.44%
↓ 4853.44%
Gross Margin
92.30%
↑ 92.30%
Net Profit Margin
-4136.00%
↓ 4136.003%
ROE
-26.96%
↓ 26.96%
ROIC
-31.53%
↓ 31.53%
Avidity Biosciences, Inc. (RNA) Income Statement & Financial Overview
Review Avidity Biosciences, Inc.'s (RNA) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $2.97M | $2.34M | $2.04M | $3.54M |
| Cost of Revenue | $738000.00 | $0.00 | $687000.00 | $641000.00 |
| Gross Profit | $2.23M | $2.34M | $1.36M | $2.90M |
| Gross Profit Ratio | $0.75 | $1.00 | $0.66 | $0.82 |
| R&D Expenses | $95.63M | $77.20M | $63.94M | $66.83M |
| SG&A Expenses | $28.34M | $23.27M | $20.73M | $13.26M |
| Operating Expenses | $123.96M | $100.47M | $84.67M | $80.09M |
| Total Costs & Expenses | $123.96M | $100.47M | $84.67M | $80.73M |
| Interest Income | $18.53M | $17.97M | $11.95M | $8.43M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $738000.00 | $710000.00 | $687000.00 | $641000.00 |
| EBITDA | -$120.25M | -$97.42M | -$82.63M | -$76.55M |
| EBITDA Ratio | -$40.45 | -$41.71 | -$40.40 | -$21.60 |
| Operating Income | -$120.99M | -$98.13M | -$82.63M | -$77.19M |
| Operating Income Ratio | -$40.70 | -$42.009 | -$40.40 | -$21.79 |
| Other Income/Expenses (Net) | $18.73M | $17.74M | $11.83M | $8.33M |
| Income Before Tax | -$102.26M | -$80.40M | -$70.79M | -$68.86M |
| Income Before Tax Ratio | -$34.40 | -$34.42 | -$34.62 | -$19.43 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $597724.00 |
| Net Income | -$102.26M | -$80.40M | -$70.79M | -$68.86M |
| Net Income Ratio | -$34.40 | -$34.42 | -$34.62 | -$19.43 |
| EPS | -$0.80 | -$0.65 | -$0.66 | -$0.79 |
| Diluted EPS | -$0.80 | -$0.65 | -$0.66 | -$0.79 |
| Weighted Avg Shares Outstanding | $128.50M | $123.38M | $106.93M | $87.21M |
| Weighted Avg Shares Outstanding (Diluted) | $128.50M | $123.38M | $106.93M | $87.21M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan